Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - Is there a safe dose?

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 128-131

  Law, Siu Tong ^a   Li, K K ^a   Ho, Y Y ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Acquired Fanconi syndrome; Adefovir dipivoxil therapy; Chronic hepatitis B infection; Hypophosphatemia

Indexed keywords

ADEFOVIR DIPIVOXIL; CALCIUM; CREATININE; PHOSPHATE;

AGED; ANTIVIRAL ACTIVITY; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; LOW DRUG DOSE; NEPHROTOXICITY; NOTE; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; SIDE EFFECT;

ADENINE; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FANCONI SYNDROME; FEMALE; HEPATITIS B, CHRONIC; HUMANS; ORGANOPHOSPHONATES;

EID: 84858000346     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01278.x     Document Type: Note

References (15)

1. Lavanchy D Hepatitis B virus epidemiology, disease burden, treatment, and current and merging prevention and control measures. Journal of Viral Hepatitis, 2004;11:97-107. (Pubitemid 38365759)
2. Beasley RP Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer, 1988;61:1942-1956.
3. Bosch FX, Ribes J, Cleries R, Diaz M Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease, 2005;9:191-211.
4. Izzedine H, Launay-Vacher V, Deray G Antiviral drug-induced nephrotoxicity. American Journal of Kidney Diseases, 2005;45:804-817. (Pubitemid 43181039)
5. Brosgart C (1999) GS-417: a randomized, double-blind study of adefovir dipivoxil (ADV) at two dose levels (120 mg 60 mg) as part of combination therapy in NRTI-experienced patients with no prior PI therapy. Oral presentation, 12th International Conference on Antiviral Research; 1999 Mar 21-26.
6. Marcellin P, Chang T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine, 2003;348:808-816. (Pubitemid 36245757)
7. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008;48:750-758.
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B. New England Journal of Medicine, 2003;348:800-807. (Pubitemid 36245756)
9. Hadziyannis S, Tassopoulos N, Heathcote EJ et al. Long-term (3-year) therapy with adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med, 2005;352:2673-2681. (Pubitemid 41007822)
10. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine- resistant hepatitis B in pre- and postliver transplantation patients. Hepatology, 2003;38:1419-1427. (Pubitemid 37466968)
11. Peters MG, Hann H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine- resistant chronic hepatitis B. Gastroenterology, 2004;126:91-101. (Pubitemid 38040727)
12. Benhamou Y, Thibault V, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. Journal of Hepatology, 2006;44:62-67. (Pubitemid 41772517)
13. Ahmad M Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. Journal of Postgraduate Medicine, 2006;52:296-297. (Pubitemid 44862772)
14. Izzedine H, Hulot JS, Launay-Vacher V et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney International, 2004;66:1153-1158. (Pubitemid 39121022)
15. Hostetler KY Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Research, 2009;82:A84-A98.